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A B S T R A C T
Oxidative stress is implicated as an important factor in the development of Alzheimer’s disease (AD). In
the present study, we have investigated the effects of edaravone (9 mg/kg, 3-methyl-1-phenyl-2-
pyrazolin-5-one), a free radical scavenger, in a streptozotocin (STZ-3 mg/kg) induced rat model of
sporadic AD (sAD). Treatment with edaravone signiﬁcantly improved STZ-induced cognitive damage as
evaluated in Morris water maze and step-down tests and markedly restored changes in malondialde-
hyde (MDA), 4-hydroxy-2-nonenal (4-HNE) adducts, hydroxyl radical (OH), hydrogen peroxide (H2O2),
total superoxide dismutase (T-SOD), reduced glutathione (GSH), glutathione peroxidase (GPx) and
protein carbonyl (PC) levels. In addition, histomorphological observations conﬁrmed the protective
effect of edaravone on neuronal degeneration. Moreover, hyperphosphorylation of tau resulting from
intracerebroventricular streptozotocin (ICV-STZ) injection was decreased by the administration of
edaravone. These results provide experimental evidence demonstrating preventive effects of edaravone
on cognitive dysfunction, oxidative stress and hyperphosphorylation of tau in ICV-STZ rats. Since
edaravone has been used for treatment of patients with stroke, it represents a safe and established
therapeutic intervention that has the potential for a novel application in the treatment of age-related
neurodegenerative disorders associated with cognitive decline, such as AD.
 2013 The Authors. Published by Elsevier Inc. 
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Alzheimer’s disease (AD) is an age-related, progressive neuro-
degenerative disorder. This condition is characterized by deteriora-
tion of cognitive function including behavioral impairments and
memory deﬁcits and is associated with pathological aggregations of
the amyloidb (Ab) peptide and neuroﬁbrillary tangles of aggregated
hyperphosphorylated tau protein in the brain. Although the exact
etiology of AD is unknown, there exists considerable evidence* Corresponding author at: No. 23, Youzheng Street, Nangang District, Harbin
City, Heilongjiang Province, China. Tel.: +86 0451 85555026;
fax: +86 0451 53661120.
E-mail addresses: zhouss613008@126.com (S. Zhou),
zfx0001@126.com (L. Zhang).
1 These authors contributed equally to this work.
0161-813X 2013 The Authors. Published by Elsevier Inc. 
http://dx.doi.org/10.1016/j.neuro.2013.07.007
Open access under CC BY licenseimplying that abnormal generation of free radicals may underlie the
development and accompanying neuronal deterioration of AD
(Markesbery, 1999; Su et al., 2008). Excesses in reactive oxygen
species (ROS) and free radical generation, as induced by oxidative
metabolism imbalance, lead to a range of changes in cellular
structure and function (Smith et al., 2010). These changes including
protein and DNA injury, energy deﬁciency, inﬂammation, mito-
chondrial dysfunction, tau hyperphosphorylation and Ab over-
expression, all of which play important roles in the acceleration of
aging and age-related neurodegenerative disorders (Pratico and
Delanty, 2000; Melov et al., 2007; Zawia et al., 2009; Coppieters and
Dragunow, 2011). Therefore, free radical scavengers and antiox-
idants, which have the capacity of neutralizing free radicals, have
been proposed as therapeutic agents for delaying, inhibiting or
reversing the pathological process of neurodegenerative disorders
(Uttara et al., 2009).
Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) is a potent
free radical scavenger and it has been demonstrated that
edaravone exerts beneﬁcial effects against oxidative stress in
acute ischemic stroke patients (Yoshida et al., 2006). In addition to.
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neuroprotective effects upon Amyotrophic lateral sclerosis (ALS)
and Parkinson’s disease (PD), and in animal models of these
conditions as demonstrated in vivo and in vitro (Kikuchi et al.,
2011). Taken together, these ﬁndings suggest that edaravone may
be effective in the treatment of neurodegenerative disorders
associated with oxidative stress, such as AD.
Streptozotocin (STZ), a glucosamine compound which, when
metabolized, generates a cytotoxic product that induces preferen-
tial damage in pancreatic b cells. Interestingly, intracerebroven-
tricular (ICV) administration of a sub-diabetogenic dose of STZ in
rats has been shown to induce cognitive dysfunction, impaired
intracerebral glucose and energy metabolism, increased oxidative
stress, hyperphosphorylation of tau protein and other neuropath-
ological and biochemical changes which are similar to those
observed in sporadic Alzheimer’s disease (Sharma and Gupta,
2001; Grunblatt et al., 2007; Salkovic-Petrisic and Hoyer, 2007).
Therefore, ICV-STZ was applied to establish a valid experimental
model of the early pathophysiological alterations in sAD (Salkovic-
Petrisic and Hoyer, 2007; Salkovic-Petrisic et al., 2011).
The present study was designed to investigate the effects of
edaravone, a potent free radical scavenger, in the intracerebroven-
tricular streptozotocin (ICV-STZ) rat model. Speciﬁcally, we
focused upon the capacity for edaravone to modulate learning
and memory impairments, oxidative stress and tau protein
phosphorylation in this rat model of sAD.
2. Materials and methods
2.1. Animals
Adult male Sprague-Dawley rats weighing 320–350 g (5–7
months) were obtained from the Beijing Vital River Laboratory
Animal Technology Co. Ltd in the People’s Republic of China. The
animals were placed in a quiet room with a 12 h light/dark cycle, an
ambient temperature of 23  2 8C and a relative humidity of 56  4%.
All surgeries were performed under anesthesia using a 10% chloral
hydrate solution. All efforts were made to minimize animal suffering.
All animal procedures performed in this work followed guidelines in
accordance with the Regulations for the Administration of Affairs
Concerning Experimental Animals, and approved by the animal care
and welfare committee of Harbin Medical University.
2.2. Drugs and chemicals
Streptozotocin (STZ) from Sigma Chemical Co., St. Louis, USA was
dissolved in artiﬁcial cerebrospinal ﬂuid (a-CSF – 2.9 mM KCl,
147 mM NaCl, 1.7 mM CaCl2, 1.6 mM MgCl2, 2.2 mM D-glucose) in a
25 mg/ml solution. This solution was prepared immediately prior to
injection. Edaravone (MCI-186, 3-methyl-1-phenyl-2-pyrazolin-5-
one) purchased from Calbiochem, Germany was dissolved in 1 N
NaOH, diluted with distilled water, and pH-adjusted to 7.4 with 1 N
HCl according to the manufacturer’s instructions. All bioluminescent
assay kits were purchased from Nanjing Jiancheng Bioengineering
Institute, Jiangsu, China. The nissl staining kit was purchased fromFig. 1. The experimental design treatment schedule and intervals for estimation of var
water maze, BBT = Beam balance test, and SAC = sacriﬁced.the Beyotime Institute of Biotechnology, Shanghai, China. Total tau,
ser396-phosphorylated tau, thr181-phosphorylated tau and b-
actin-speciﬁc antibodies were purchased from Santa Cruz Biotech-
nology Inc., USA and the polyclonal 4-HNE antibody was purchased
from Abcam Biotechnology Inc., USA. The secondary antibodies were
purchased from the Zhongshan Company of Beijing, China. All other
chemicals were of analytical reagent grade.
2.3. Experimental design
After a week of adaption to colony room conditions the rats
were randomly divided into six groups: Group 1-Sham (S): sham
operated rats were infused with a-CSF in each ventricle on days 1
and 3, and the animals were administered with distilled water
(0.5 ml b.i.d. intraperitoneally) as a vehicle of edaravone for two
weeks following the ﬁrst day after surgery in each group. Group 2-
Edaravone + S: sham operated rats were administered with 9 mg/
kg b.i.d. i.p. of edaravone. Group 3-Lesion (L): rats were performed
with bilaterally ICV infusion of STZ on days 1 and 3, and the rats
were treated with the same vehicle as S group. Group 4-Edaravone
1 + L: ICV-STZ rats were immediately administered with edaravone
1 mg/kg b.i.d. i.p. after ﬁrst STZ infusion for two weeks. Similar as
group 4, animals in groups 5 (Edaravone 3 + L) and 6 (Edaravone
9 + L) were infused with ICV-STZ on days 1 and 3, and treated with
edaravone at doses of 3 mg/kg and 9 mg/kg respectively for two
weeks following the ﬁrst day after surgery.
All behavioral tests were carried out to evaluate the capacity of
learning and memory for each group between day 15 and day 24.
On day 25, the rats were sacriﬁced for assay of T-SOD, MDA, GSH,
GPx as a dose dependent study. Based on the above results, the
dose of 9 mg/kg was choosed for further study, including the
content of content of PC, H2O2 and hydroxy radical, the content of
4-HNE adducts and phosphorylation levels of tau protein. Fig. 1
shows the treatment schedule design and time intervals for
estimations of the various parameters.
2.4. Surgical procedure
Animals were anesthetized using a 10% chloral hydrate solution
of 3 ml/kg administered intraperitoneally. The head was posi-
tioned in a stereotaxic apparatus and skull exposed. Two holes
were drilled through the skull for bilateral placement of a micro-
injector into the lateral cerebral ventricles using the following
coordinates: 0.8 mm posterior to bregma; 1.6 mm lateral to the
sagittal suture; and 4.0 mm ventral from the surface of the brain
(Ishrat et al., 2009b). The STZ solution was infused slowly (1 ml/
min) into each ventricle on days 1 and 3. The sham group received
the same surgery but infused with an equal volume of a-CSF only.
2.5. Memory and learning test
2.5.1. Morris water maze test
Spatial learning and memory were tested with use of a Morris
water maze (MWM) (Morris, 1984). The water maze was a circular
black tank (150 cm diameter, 60 cm height) with an automaticious parameters. ICV-STZ = intracerebroventricular streptozotocin, MWM = Morris
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maze was ﬁlled with water to a depth of 40 cm. Four equally spaced
locations at the periphery of the pool (North, South, East and West)
divided the pool into 4 quadrants, and were used as start points. An
escape platform of 10 cm diameter was placed 2 cm below the surface
of the water at a constant location in the center of one of the
quadrants. The animals were subjected to a daily session of four
training trials with an inter-trial interval of 30 min for ﬁve
consecutive days. Prior to training, rats were allowed to swim freely
in the pool for 60 s without the platform. The rats were permitted a
maximal time of 60 s to ﬁnd the hidden platform and allowed to
remain on the platform for 30 s before commencement of the next
trial. If the rat failed to locate the hidden platform within 60 s, it was
gently placed on the platform and allowed to remain there for a 30 s
period. Latencies to locate the platform were recorded in training
trials. One day after the training phase, a probe test was conducted by
removing the platform. Rats were allowed to swim freely in the pool
for 60 s. The time spent in the target quadrant in which the platform
had previously been located during training phase was recorded. This
parameter provided an index of the degree of memory consolidation.
2.5.2. Balance beam test
The balance beam is a test of motor coordination. After
completion of the MWM test, the balance beam test was
administered. Since balance can inﬂuence performance on the
step-down test (described below), it was considered important to
include an assessment of balance. Animals were trained to traverse a
cylindrical beam with a length of 200 cm and diameter of 2.5 cm. A
black platform (7 cm  4 cm) was positioned at one end of the beam
as a start, and a black plastic box (15 cm  15 cm  8 cm) was placed
at the other end as a type of reinforcement for rewarding the animal
to traverse the beam. The apparatus was suspended 90 cm above a
cushion, which protected animals from injury due to falls, and was
positioned 50 cm from a wall. Rats were moved into the testing room
one hour before the test to adapt to the environment. The time
required to traverse the beam during two trials was recorded. The
maximal transversal time allowed was 60 s.
2.5.3. Step-down test
The step-down test was selected as a method to evaluate
potential deﬁcits in memory retention. This test was administered
after all rats had completed the MWM test. The step-down passive
avoidance apparatus consisted of a box (25 cm  25 cm  75 cm)
with a stainless-steel grid ﬂoor and a round safe platform (8 cm
diameter, 5 cm height) positioned in one corner on the grids. In the
acquisition trial period, each rat was placed gently on the safe
platform. The initial latency (IL) to step down from the platform
was recorded, and an electric foot shock (3 s 0.4 mA) was
immediately delivered through the ﬂoor grids. After a series of
repeated trials, the rats eventually remained on the platform. This
training session lasted 300 s. Twenty-four hours later, the
retention latency (RL) time was measured and recorded in the
same manner as described for the acquisition trial. If the rat did not
step down from the platform within 300 s, the trial was terminated
and the retention latency was recorded as a maximum value of
300 s. Whenever the rat stepped down from the platform this was
counted as an error and the number of errors was recorded. Each
rat received only one training session and only one test session.
Deﬁcits in acquisition and retention of memory were indicated by
decreased latencies and increased number of errors in the task.
2.6. Measurement of biochemical parameters
2.6.1. Tissue preparation
After completion of all behavioral tests on day 25, the rats
were sacriﬁced by decapitation. Whole brains were removedquickly and prepared for assay. The brains were rinsed with
chilled saline and cerebral cortex and hippocampus were
dissected on ice according to coordinates indicated in the rat
brain atlas. The two dissected brain structures were weighed
and homogenized in ice-cold normal saline to achieve a 10%
homogenate solution (1/9, tissue/saline, w/v). The homogenate
was centrifuged at 4000 rpm for 10 min at 4 8C to separate
nuclear debris and an aliquot of the supernatant removed for
estimation of SOD, MDA, GSH, GPx, H2O2 and
OH. The
remaining supernatant was further centrifuged at 10,000  g
for 20 min at 4 8C to generate the post-mitochondrial superna-
tant (PMS), which was used for PC assays.
2.6.2. Biochemical analysis
The analyses of T-SOD, MDA, GSH, GSH-Px, H2O2 and
OH, and
PC levels were performed according to the protocols provided by
the Nanjing Jiancheng Bioengineering Institute (Jiangsu, China)
with a UV1700 spectrophotometer (Shimadzu, Japan) and the
method described in the references.
SOD activity was analyzed according to the directions
described in the kit. A competitive inhibition assay was
administered using xanthine–xanthine oxidase-generated O2 to
reduce nitroblue tetrazolium (NBT) to blue formazan. One unit (U)
of SOD activity was deﬁned as the amount of enzyme required to
reduce NBT to 50% of maximum. The maximum absorbance was
read at 550 nm and enzymatic activity was presented as U/mg
protein/min.
MDA content was determined using thiobarbituric acid reactive
substances, and the adduct was measured at 532 nm. MDA content
was expressed as nmol/mg protein. Blanks for each sample were
prepared and assessed identically to correct for the contribution of
A532 to the sample.
A thiolspeciﬁc reagent, dithionitrobenzoic acid (DTNB), was
used to assay the GSH content, and the yellow mixture was
measured at 420 nm. GSH content was expressed as mg GSH/g
protein.
GSH-Px activity was estimated by the analysis of reduced GSH
in the enzymatic reaction (Sedlak and Lindsay, 1968). One unit of
GSH-Px activity was deﬁned as the amount of decrease in 1 mmol/
mg wet tissue per minute GSH concentration after subtraction of
the non-enzymatic mode at 37 8C as suggested in the protocol of
the commercial kit. GSH-Px activity was expressed as U/mg
protein/min.
Hydrogen peroxide can form a complex with ammonium
molybdate and the mixture was measured at 405 nm. Hydrogen
peroxide content was expressed as mmol/g protein.
Hydroxy radical level was measured as previously described
(Steiner and Babbs, 1990) and the concentration of hydroxyl
radical was expressed as nmol/mg protein.
The PC level was measured as previously described (Ishrat et al.,
2009a). Absorbance was recorded at 360 nm in a spectrophotom-
eter. The PC level was then expressed as nmol carbonyl/mg protein.
2.6.3. Total protein assay
Protein concentrations were determined by the Coomassie
brilliant blue protein binding method (Bradford, 1976) using
bovine serum albumin (BSA) as a standard. The sample was
diluted to a 1% concentration and absorbance was measured at
595 nm.
2.7. Nissl staining
Rats were deeply anesthetized with 10% chloral hydrate and
subjected to transaortic perfusion with phosphate-buffered saline
(PBS) followed by 4% paraformaldehyde to ﬁx the brain. The entire
brain was then carefully extracted and maintained in 4%
Fig. 2. Effect of edaravone treatment on the performance of training (A) and probe
(B) trials in a MWM test. Values are expressed as mean  SD in seconds. The average
escape latency on the ﬁfth day was signiﬁcantly prolonged in the L group as compared
with the S group, and the average time in the target quadrant was signiﬁcantly reduced
in the L group as compared with the S group (*P < 0.05, S vs. L group), indicating a
learning performance deﬁcit in the ICV-STZ lesioned rats. The prolonged escape latency
and reduced time in the target quadrant observed in the L group were signiﬁcantly
attenuated by Edaravone treatment in Edaravone + L group (#P < 0.05, ##P < 0.01, L vs.
Edaravone 9 + L group).
Fig. 3. Balance beam test scores of the four groups. Values are expressed as
mean  SD in seconds. No overall statistically signiﬁcant differences were obtained
among the four groups. Administration of edaravone does not alter balance as
indicated in the latency times to traverse the elevated beam in this test using a 2.5
diameter cylindrical beam (P > 0.05).
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dehydrated and embedded in parafﬁn. Coronal sections were
evaluated at 1.8–2.0 mm rostral to the optic chiasm. Sections
(4 mm) were prepared and subjected to nissl staining as described
in the protocol of the instructions.
2.8. Western blot
Cerebral cortex and hippocampus were dissected, snap-
frozen in liquid nitrogen and stored at 80 8C. Western blot was
used to assay the levels of 4-HNE protein adducts, tau, ser396-
phosphorylated tau and thr181-phosphorylated tau. In brief,
tissues were homogenized in a RIPA buffer (Applygen Technol-
ogies Inc.) with protease inhibitors. The total amount of protein
was determined by the bicinchoninic acid protein assay
(Applygen Technologies Inc.). Samples were separated by
SDS–PAGE and transferred to nitrocellulose membranes, which
were blocked by incubation in 3% (w/v) BSA dissolved in TBS-T.
The membranes were incubated at room temperature with 4-
HNE, total tau, ser396-phosphorylated tau, thr181-phosphory-
lated tau or b-actin-speciﬁc antibodies. Protein bands were then
detected as resulting from incubation with conjugates of
secondary antibodies.
2.9. Statistical analysis
The data were expressed as the mean  SD and were
evaluated using one-way ANOVA followed by LSD (equal variances
or homogeneity of variance assumed after the variable transfor-
mation) or Dunnett’s T3 (equal variances not assumed after the
variable justiﬁcation) tests for post hoc comparisons between
groups. Statistical signiﬁcance was accepted when P < 0.05.
3. Results
3.1. Behavioral observations
3.1.1. Edaravone treatment decreased escape latency in training trials
and increased time in target quadrant in Morris water maze probe test
in ICV-STZ rats
Latencies to locate the hidden platform below the water
surface gradually diminished in all six groups over the ﬁve days
of MWM training. Average latency to locate the hidden platform
on the ﬁfth day of training trials was signiﬁcantly (P < 0.05)
prolonged in the L group as compared with the S group.
Edaravone (9 mg/kg) treatment signiﬁcantly (P < 0.05) reversed
the STZ induced learning deﬁcits as observed in the Edaravone
9 + L group (Fig. 2A). The amount of time in the target quadrant
was signiﬁcantly less in the L group as compared with the S
group. Edaravone (9 mg/kg) treatment signiﬁcantly (P < 0.05)
attenuated STZ induced memory deﬁcits in the L group as
indicated by increased amounts of time in the target quadrant in
the Edaravone 9 + L group (Fig. 2B). No statistically signiﬁcant
differences in latencies and the amount of time in the target
quadrant were obtained between low doses (1 mg/kg and 3 mg/
kg) Edaravone treatment group and L group. Taken together,
these results revealed an improved acquisition and retention of
memory with edaravone treatment in ICV-STZ rats.
3.1.2. Edaravone does not alter balance in ICV-STZ rats as assessed in
the balance beam test
In the balance beam test, rats were placed on the beam to assess
their balance and coordination by measuring the time required to
traverse the beam. No statistically signiﬁcant differences in
transversal times were obtained among the six groups (Fig. 3,
P > 0.05).3.1.3. Edaravone treatment increased retention latency and reduced
the number of errors in the step-down test in ICV-STZ rats
In the step-down test, latency was deﬁned as the time for the
ﬁrst step-down onto the electric grid. In addition, the number of
errors as recorded whenever the rat stepped down from the
platform, was counted. As shown in Fig. 4A and B, latencies
decreased while error-number signiﬁcantly (P < 0.05) increased in
the L group as compared to the S group. Latencies were prolonged
while error-number signiﬁcantly (P < 0.05) reduced in Edaravone
9 + L group as compared with the L group, suggesting that
edaravone (9 mg/kg) improved acquisition and retention of
memory in ICV-STZ rats.
Fig. 4. Effect of edaravone treatment on latency (A) and error number (B) in the
step-down test. Values are expressed as mean  SD in seconds (A) and number (B).
The latency of the L group was signiﬁcantly reduced and error number signiﬁcantly
increased as compared with that of the S group (*P < 0.05, S vs. L group). The latency
increased and error number decreased signiﬁcantly in Edaravone 9 + L group as
compared with L group (#P < 0.05, ##P < 0.01 Edaravone 9 + L group vs. L).
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3.2.1. Edaravone treatment restored T-SOD and GPx activities in the
cerebral cortex and hippocampus of ICV-STZ rats
The effects of edaravone treatment on the activities of T-SOD
and GPx in the cerebral cortex and hippocampus of ICV-STZ rats
are shown in Table 1. Activities of T-SOD and GPx were
signiﬁcantly (P < 0.05) decreased in the L group as compared
with the S group in cerebral cortex and hippocampus. Edaravone
supplement signiﬁcantly (P < 0.01) increased T-SOD and GPx
activities in the Edaravone 9 + L group as compared with the L
group. Edaravone treatment (3 mg/kg) also signiﬁcantly in-
creased T-SOD activities in the cortex in the Edarvone 3 + L
group as compared with the L group. There were no signiﬁcant
(P > 0.05) differences between the Edaravone + S and S groups.Table 1
Values are presented as mean  SD and were analyzed by one-way ANOVA. ICV-STZ caused
level of an antioxidant agent (GSH) in the L group as compared with the S group (*P < 0.05 L
enzymes in the Edaravone treatment groups (#P < 0.05 Edaravone 3 + L vs. L group, ##P < 0.
content of GSH in the Edaravone 9 + L group (#P < 0.05, ##P < 0.01 Edaravone 9 + L vs. L group
with the S group (*P < 0.05 L vs. S group). Administration of edaravone signiﬁcantly restore
group, ##P < 0.01 Edaravone 9 + L vs. L group). Measuring unit of each parameter: T-SOD U
Groups SOD MDA 
Cortex Hippocampus Cortex Hippoca
Sham (S) 51.7  4.1 52.4  3.0 5.4  0.7 3.5  0.7
Edaravone + S 50.4  3.1 53.3  4.2 5.4  0.8 3.9  0.5
Lesion (L) 37.7  3.3* 34.8  3.2* 10.9  1.9* 5.3  0.8
Edaravone 1 + L 39.1  3.0 36.0  3.6 9.1  0.8 5.3  0.8
Edaravone 3 + L 43.6  6.2# 38.1  4.9 7.8  0.6# 4.8  0.6
Edaravone 9 + L 48.6  4.7## 44.9  4.1## 6.0  0.5## 4.0  0.53.2.2. Edaravone treatment reduced MDA levels in the cerebral cortex
and hippocampus of ICV-STZ rats
The effect of edaravone treatment on MDA levels in the cerebral
cortex and hippocampus of ICV-STZ rats is shown in Table 1. MDA
levels were signiﬁcantly (P < 0.05) increased in the L group as
compared with the S group. The augmentation of MDA in the L
group was signiﬁcantly decreased by edaravone 3 mg/kg (P < 0.05)
and 9 mg/kg (P < 0.01) treatment in the cortex. However, the
augmentation of MDA in the L group was signiﬁcantly (P < 0.01)
decrease by edaravone 9 mg/kg treatment only in the hippocam-
pus. There were no signiﬁcant (P > 0.05) differences between the
Edaravone + S group and the S group.
3.2.3. Edaravone treatment restored GSH levels in the cerebral cortex
and hippocampus of ICV-STZ rats
The effect of edaravone treatment on GSH levels in the cerebral
cortex and hippocampus of ICV-STZ rats is shown in Table 1. Levels
of GSH were signiﬁcantly (P < 0.05) depleted in the L group as
compared with the S group. GSH reductions by ICV-STZ were
signiﬁcantly ameliorated by edaravone (9 mg/kg) supplementa-
tion in the hippocampus (P < 0.05) and cortex (P < 0.01). The levels
of GSH were not signiﬁcantly (P > 0.05) changed by edaravone
alone as revealed by the absence of signiﬁcant differences between
the Edaravone + S group and the S group.
3.2.4. Edarvone treatment restored hydroxyl radical, H2O2 and PC
levels in the cerebral cortex and hippocampus of ICV-STZ rats
The effect of edaravone treatment on hydroxyl radical, H2O2
and PC levels in the cerebral cortex and hippocampus of ICV-STZ
rats is shown in Table 2. Levels of hydroxyl radical, H2O2 and PC
were signiﬁcantly (P < 0.05) increased in the L group as compared
with S group. The augmentations of hydroxyl radical and H2O2
levels by ICV-STZ were signiﬁcantly (P < 0.01) ameliorated by
edaravone (9 mg/kg) administration in both hippocampus and
cortex. The increasing of PC level by ICV-STZ was signiﬁcantly
(P < 0.01) restored by edaravone (9 mg/kg) in the cortex. The
levels of hydroxyl radical, H2O2 and PC were not signiﬁcantly
(P > 0.05) changed between the Edaravone + S group and the S
group.
3.3. Histomorphological observation
Nissl stain was used to detect histomorphological changes in
cerebral cortex and hippocampal neurons following ICV-STZ
injection as shown in Fig. 5. Photomicrographs of coronal sections
were taken at 200 magniﬁcation from the S (A, D), L (B, E) and
Edaravone 9 + L (C, F) groups. Nissl staining revealed cell loss and
injured neurons in the cerebral cortex and hippocampus of the L
group. Compared to the L group, quantitative cell count revealed an a signiﬁcant decrease in the activities of antioxidant enzymes (T-SOD and GPx) and the
 vs. S group). Administration of edaravone signiﬁcantly restored the activities of these
01 Edaravone 9 + L vs. L group). Administration of edaravone signiﬁcantly restored the
). ICV-STZ caused a signiﬁcant increase in the levels of MDA in the L group as compared
d the levels of MDA in the Edaravone treatment groups (#P < 0.05 Edaravone 3 + L vs. L
/mg protein/min, MDA nmol/mg protein, GPx U/mg protein/min, GSH mg/g protein.
GPx GSH
mpus Cortex Hippocampus Cortex Hippocampus
2 29.3  2.6 42.4  5.6 17.8  3.2 19.0  2.3
 27.5  2.9 45.6  6.4 18.1  4.4 18.7  3.5
* 17.8  1.5* 34.4  5.3* 10.9  1.9* 12.3  2.5*
 17.5  2.4 35.6  3.1 10.7  2.0 13.3  3.5
 18.8  4.0 37.2  3.6 12.0  3.1 16.0  1.4
## 23.3  4.1## 41.0  6.4## 15.5  2.6## 20.0  3.7#
Table 2
Values are presented as mean  SD and were analyzed by one-way ANOVA. ICV-STZ caused a signiﬁcant increase in the levels of H2O2, hydroxy radical and PC in the L group as
compared with the S group (*P < 0.05 L vs. S group). Administration of edaravone signiﬁcantly restored the levels of H2O2, hydroxy radical and PC in the Edaravone 9 + L group
(##P < 0.01 Edaravone 9 + L vs. L group). Measuring unit of each parameter: H2O2 mmol/g protein, hydroxy radical nmol/mg protein, PC nmol/mg protein.
Groups H2O2 Hydroxy radical PC
Cortex Hippocampus Cortex Hippocampus Cortex Hippocampus
Sham (S) 36.8  1.6 40.2  3.3 1.4  0.1 1.9  0.2 26.0  2.6 24.0  2.5
Edaravone + S 35.6  2.7 37.8  2.8 1.4  0.1 1.8  0.2 26.2  2.0 23.3  2.5
Lesion (L) 76.0  9.1* 80.8  5.7* 2.6  0.2* 3.0  0.2* 35.6  3.1* 31.0  3.9*
Edaravone 9 + L 54.8  6.9## 55.8  10.8## 2.0  0.2## 2.6  0.3## 31.2  3.4## 28.4  2.9
Fig. 5. Nissl stain in the cerebral cortex and the CA1 region of hippocampus. S group (A, D) indicate the normal neurons in cerebral cortex and hippocampus (A, D). L group (B,
E) revealed cell loss in these zones after ICV-STZ in rats. Edaravone markedly decreases the loss of the cells in cerebral cortex and hippocampus (C, F). Quantiﬁcation of neuron
numbers was shown in G. (*P < 0.05 L group vs. S group, #P < 0.05 Edaravone 9 + L group vs. L group).
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Fig. 6. Effect of edaravone treatment on 4-HNE adducts. 4-HNE adducts in the hippocampal (A) and cerebral cortical (B) proteins were determined by Western blots.
Quantiﬁcation of adducts (C, D) was normalized against b-actin. The relative values from each group were presented as mean  SD. The level of 4-HNE adducts was signiﬁcantly
increased in the L group as compared to the S group. Treatment with edaravone signiﬁcantly restored these enhanced levels of 4-HNE adducts as induced by ICV-STZ (*P < 0.05 L
group vs. S group, #P < 0.05 Edaravone 9 + L group vs. L group, n = 6).
S. Zhou et al. / NeuroToxicology 38 (2013) 136–145142increase in the number of surviving neurons in the Edaravone 9 + L
group (Fig. 5G).
3.4. Effect of edaravone on 4-HNE adducts levels
4-HNE is an a,b unsaturated aldehyde produced during
oxidation in membranes. 4-HNE can react with proteins to form
4-HNE adducts, and the levels of 4-HNE adducts provide an
indication of lipid peroxidation (Cutler et al., 2004). Levels of 4-
HNE adducts were measured in the hippocampus and cerebral
cortex of ICV-STZ rats by Western-blot. Western blots of 4-HNE
protein adducts in hippocampal and cortex from S, L and
Edaravone 9 + L rats are shown in Fig. 6A and B and quantiﬁed
results of 4-HNE protein adducts levels from the above three
groups of rats are shown in Fig. 6C and D. ICV-STZ infused rats had
signiﬁcantly increased 4-HNE adducts as compared to the S group
in both hippocampus and cerebral cortex. In contrast, ICV-STZ
infused rats with edaravone treatment showed a signiﬁcant
reduction in 4-HNE protein adducts.
3.5. Effect of edaravone on phosphorylated tau proteins
Total tau-protein expression was not signiﬁcantly changed
among the groups (P > 0.05) as shown in Fig. 7A and D.
Phosphorylated tau was evaluated in the hippocampus and the
cerebral cortex using the ser396-p-tau and thr181-p-tau anti-
bodies. Hyperphosphorylation of tau at ser396 and thr181 as
induced by STZ was signiﬁcantly (P < 0.05) reduced in both
hippocampus and cerebral cortex after administration of edar-
avone, Fig. 7A–C.
4. Discussion
The present results demonstrate that ICV-STZ induced learning
and memory impairments in rats while edaravone treatment of
these rats signiﬁcantly improved their performance on behavioral
tests of learning and memory as well as on parameters of oxidative
stress, neuronal histomorphology and tau protein phosphoryla-
tion. Edaravone, a potent free radical scavenger, has been used
safely for more than 10 years. In addition to functioning as a
scavenger of free radicals, edaravone has shown anti-oxidative,
anti-apoptotic, anti-necrotic and anti-cytokine effects in animalmodels of various diseases (Kikuchi et al., 2012). However, effects
of edaravone in sAD-related cognitive impairment and neuropath-
ological changes have not been reported. Accordingly, we
considered it is worthwhile to investigate the potential for
edaravone to function as a neuroprotectant in an animal model
of experimental sporadic dementia induced by STZ. In this study
we investigated the effects of edaravone in modulating ICV-STZ
induced cognitive dysfunction in rats, as well as the major
biochemical components of neurodegeneration in this sAD model.
In our initial studies, we selected the doses of edaravone (1 mg/
kg, 3 mg/kg and 9 mg/kg) to study. In previous studies, these doses
exerted no toxic effects in rats (Tabrizchi, 2000). Our results
showed that the dose of 9 mg/kg edaravone exerted the maximal
effectiveness in the treatment of ICV-STZ rats. Previous studies
have provided data on the concentrations of edaravone in the brain
of rats. These investigators have found that the relative ratio of
plasma to cerebral spinal ﬂuid levels of edaravone was estimated
to be between 50 and 65%. During administration of edaravone
at1 mg/kg/h for 3 h, concertrations of edaravone in plasma and
cerebral spinal ﬂuid were 375 ng/ml and 244 ng/ml, respectively
(Tabrizchi, 2000). Moreover, another study found that edaravone
has preventive effects on the degeneration of spinal motor neurons
in the ALS model mice. In addition, the results of serum
concentration of edaravone after a single intraperitoneal injection
into the mice showed that a dose dependent elevation of serum
concentration of edaravone was observed and the max serum
concentration was 600–1100 ng/ml at 5 min after 10 mg/kg
administration (Ito et al., 2008).
The Morris water maze test was employed to assess spatial
learning and memory based on a reward mechanism. Rats readily
attempt to escape from the water bath by locating an escape
platform in a target quadrant. Therefore, escape latencies, which
are the times required to locate the hidden platform, gradually
decrease in training trials and more time is spent in the target
quadrant in probe trials. Improvement of spatial memory by
edaravone treatment in these ICV-STZ rats was indicated by
shorter escape latencies and longer durations in the target
quadrant.
The step-down passive avoidance test was used to evaluate
non-spatial long-term memory based on the learned inhibition of a
behavior to avoid punishment (Zhao et al., 2011). In our study, this
aspect of memory showed an improvement in ICV-STZ rats
Fig. 7. Effects of edaravone on ICV-STZ-induced phosphorylated tau. The antibodies speciﬁc for ser396-phosphorylated tau, thr181-phosphorylated tau, total tau and b-actin
were used to detect levels of intracerebral phosphorylated tau proteins by Western immunoblotting in each group (*P < 0.05 L group vs. S group, #P < 0.05 Edaravone 9 + L
group vs. L group, n = 6).
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errors in step-down performance. In addition to the amygdala and
insula, recognition of fear and the detection of aversion rely on the
hippocampus and cortex (Arendt, 2001; Adolphs, 2002). Interest-
ingly, all brain structures mentioned above play vital roles in
learning and memory processing and seem to be more susceptible
to oxidative damage.
The balance beam test was included to exclude the inﬂuence of
balance upon performance in the step-down task. No signiﬁcant
differences were obtained among the groups, in particular
between the ICV-STZ and edaravone treated ICV-STZ rats. Such
ﬁndings suggest that the capacity for edaravone to prevent passive
avoidance memory deﬁcits in ICV-STZ rats was not due to
difference in their balance.
Oxidative stress which is characterized by an imbalance in
reactive oxygen species (ROS) and antioxidative defense has been
demonstrated to play a critical role in several neurodegenerative
diseases (Lin and Beal, 2006). Increasing evidence suggests that
oxidative stress is a prominent and early feature of Alzheimer’s
disease (AD) and plays an important role in its pathogenesis
(Christen et al., 2000; Barnham et al., 2004). Impaired antioxidative
systems including antioxidant enzymes (e.g. SOD and GPx) and
antioxidants (e.g. GSH) induce increased free radical generation.
The unpaired electron in the outer obit of free radicals makes them
unstable and capable of reacting with macromolecules such as
proteins, sugars, lipids and nucleic acids, leading to changes in
structure and function of neural cells in the brain (Tuppo and
Forman, 2001). Consequently, these changes induce cellular
damage, dysfunction, and cell death, eventually leading to
pathological changes as observed in conditions such as AD, agingand other neurodegenerative diseases (Fang et al., 2002). The most
abundant ROS superoxide radical (O2
) may induce formation of
the highly toxic hydroxyl radical, OH, which represents one of the
most reactive oxidants of proteins and nucleic acid. The SODs are a
group of metalloenzymes that catalyze the transformation of
superoxide radical into hydrogen peroxide, H2O2. Under physio-
logical conditions, increased SOD activity usually accompanies
increasing GPx levels and this increase of GPx detoxiﬁes the high
levels of H2O2 produced by SOD (Dringen et al., 2005). During the
detoxiﬁcation process, oxy-radicals are reduced by GPx at the
expense of GSH, the most abundant non-protein thiol that buffers
free radicals in brain tissue (Dringen et al., 2000).
Increased levels of free radicals initiate the oxidation of
polyunsaturated fatty acids leading to lipid peroxidation (Drin-
gen et al., 2000) and results in protein carbonylation (Smith et al.,
1992). Lipid peroxides further lead to production of more stable
compounds like malondialdehyde (MDA), 4-hydroxy-2-nonenal
(4-HNE) and acrolein, which initiates oxidative stress. Oxidative
damage to lipids (lipid peroxidation) and proteins (PC formation)
initially results in an alteration of cell structure, inactivation of
enzymes, followed by loss of normal physiological cell function
and eventually neuronal cell death (Mattson, 2004). Mubeen and
Stephen have shown that elevated oxidative stress resulting from
PC and 4-HNE can lead to delayed neuronal death in the frontal
cortex and is associated with mild cognitive impairment (MCI)
and AD (Ansari and Scheff, 2010). In the present study, levels of
MDA, 4HNE and PC increased and level of GSH decreased with
down-regulated biochemical activity of SOD and GPx in the brain
of ICV-STZ rats. Edaravone is effective in reducing oxidative
stress and is a promising candidate for neuroprotection in
S. Zhou et al. / NeuroToxicology 38 (2013) 136–145144reducing brain damage when applied in this model of sAD (Kaur
and Ling, 2008). Several reports have related the modulatory
effects of edaravone on lipid peroxidation, PC formation and
antioxidant enzymes as observed in hypoxia/ischemia and
ischemic–reperfusion injury experiments (Takahashi et al.,
2003; Zhang et al., 2005). In agreement with these ﬁndings,
we report here that edaravone treatment markedly restored the
biochemical changes as well as cognitive deﬁcits induced by ICV-
STZ infusion. It seems likely that this effect of edaravone could, in
part, be attributed to its potent antioxidant property.
Consistent with previous reports (Chen et al., 2012; Correia
et al., 2012), we also observed tau hyperphosphorylation induced
by ICV-STZ. Findings from several sources have indicated that
increased oxidative stress induces tau phosphorylation (Melov
et al., 2007; Clausen et al., 2012). 4-HNE and PC are the two main
products of oxidative stress. 4-HNE is a major aldehyde generated
during lipid peroxidation of unsaturated lipids in the membrane,
and it can conjugate to speciﬁc amino acid residues (e.g. lysine,
cysteine, arginine) of proteins to impair their function. For
example, HNE causes dysfunction of ion-motive ATP-ases, glucose
and glutamate transporters, enzymes involved in amyloid
metabolism, and cytoskeletal proteins (Mattson, 2009). Ikuroh
Ohsawa et al. established a transgenic mice model in which the
ability to scavenge HNE was decreased. As a result, an accumula-
tion of HNE was present, ultimately, producing hyperphosphory-
lated tau proteins within the brain of these mice. Furthermore,
under conditions of modiﬁed HNE, normal tau proteins are altered
to phosphorylated tau, and epitopes of these modiﬁed tau
represent the major conformational changes contributing to the
formation of neuroﬁbrillary tangles (NFTs), which is a prominent
pathological marker of AD (Liu et al., 2005). In addition, increased
protein carbonyl levels were found in the brains of tau transgenic
mice and this change preceded tau pathology (Dumont et al.,
2011). Our ﬁndings suggest that 4-HNE and PC may represent two
of the main toxic products in ICV-STZ induced brain injury, in part,
through their capacity to facilitate the occurrence of tau protein
hyperphosphorylation. In support of this postulate, the current
ﬁndings showed that edaravone protected the brain against ICV-
STZ lesion by detoxifying 4-HNE and PC.
NFTs exist as intracellular abnormal protein ﬁbers made up of
paired helical ﬁlaments (PHF), which are mainly composed of
aggregations of hyperphosphorylated tau. Physiologically, the
main function of tau is to maintain intracellular microtubule
stabilization. Hyperphosphorylation of tau decreases this
capacity for binding and stabilizing microtubules (Hanger
et al., 2009). Aggregation of hyperphosphorylated tau in neurons
leads to axonal transport dysfunction (Yang et al., 2007),
proteasome activity inhibition (Ren et al., 2007), consequent
impairment of the structure and function of neurons and
eventually neurodegeneration. A growing body of evidence is
accumulating which indicates that the relationship between
cognitive impairment and tau was more complex than that
which can be attributable to that of Ab alone (Arriagada et al.,
1992; Roberson et al., 2007). These ﬁndings inspired us to study
the effect of edaravone administration upon tau hyperpho-
sphorylation as induced by STZ. In our study, we found that
edaravone could reduce hyperphosphorylation of tau protein at
ser396 and thr181 in the cerebral cortex and hippocampus of
ICV-STZ rats.
In conclusion, our results demonstrate that edaravone amelio-
rated behavioral impairments of memory deﬁcit, attenuated
oxidative stress and blocked tau hyperphosphorylation in rat
brains as produced by administration of ICV-STZ. Taken together,
the present study provides further support for the potential use of
edaravone in the treatment of aging and age-related neurodegen-
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